Fennec Pharmaceuticals (FENC) Non-Current Deffered Revenue (2023 - 2025)

Fennec Pharmaceuticals (FENC) has 3 years of Non-Current Deffered Revenue data on file, last reported at $24.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $24.6 million; the trailing twelve-month figure through Dec 2025 stood at $24.6 million (changed 0.0% YoY), and the FY2025 full-year result was $24.6 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q4 2025 stood at $24.6 million, roughly flat from $24.6 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $25.0 million in Q1 2024 and bottomed at $2000.0 in Q4 2023.
• The 3-year median for Non-Current Deffered Revenue is $24.6 million (2024), against an average of $21.9 million.
• The widest annual swing landed in 2024, when Non-Current Deffered Revenue surged 1227950.0%; it then fell 1.73% in 2025.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $2000.0 in 2023, then soared by 1227950.0% to $24.6 million in 2024, then changed by 0.0% to $24.6 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $24.6 million (Q4 2025), $24.6 million (Q3 2025), and $24.6 million (Q2 2025), per Business Quant data.

Peer Comparison